Dr. Yair Levy, a hematologist with Baylor University Medical Center in Dallas, explains what chronic lymphocytic leukemia (CLL) patients need to know about game-changing targeted treatments
Patients facing a chronic lymphocytic leukemia (CLL) diagnosis often encounter complex choices about their next steps in treatment, but targeted therapy developments have really changed the game.
Here, Dr. Yair Levy, a hematologist with Baylor University Medical Center in Dallas, explains how targeted treatments, BTK inhibitors in particular, have changed how doctors approach treatment for CLL.
Dr. Yair Levy
Baylor University Medical Center in Dallas
Learn why chemotherapy is no longer the standard treatment for most chronic lymphocytic leukemia (CLL) patients and how targeted therapies like BTK inhibitors are improving outcomes.
Dr. Yair Levy
Baylor University Medical Center in Dallas
Experts say emerging treatments, including CAR T-cell therapy, BTK degraders, and bispecific antibodies, could further improve outcomes for patients in the coming years.
Sign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.
